China Tumor Ablation Report | Cetas Healthcare

September 2022

China Tumor Ablation report is the first ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Radiology, Vascular Surgery and General Surgery departments from Level 2 and Level 3 hospitals in China.

The report covers:

Tumor ablation devices: Microwave Ablation (MWA), Cryoablation, Radiofrequency Ablation (RFA), High Frequency Ultrasound (HIFU) and Irreversible Electroporation (IRE).
Procedure trends: by cancer type and modality/device type.

There are several types of medical insurance with different reimbursement proportion. The reimbursement proportion of national medical insurance is 70%. Urban resident medical insurance is 50%. As to those new-type cooperative insurance, it can be 60%, 50%, 30% or even 20%.”

– Interventional Radiologist, Tumor Ablation China

~54% of DVT procedures are performed for clots formed in the Iliac vein
~76% of venous stenting procedures use venous self-expanding stents
84% of patients are referred to interventionalists in severe stages

Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.Future trends such as immunotherapy used in combination with ablation technologies is gaining prominence. Acceptance of tumor ablation to treat cancer types such as breast cancer is expected to increase as clinical evidence suggests good patient outcomes.Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such IceCure MedTech Co. Ltd signed an exclusive distribution agreement for IceSense3 (ProSense’s brand name in China) cryoablation systems with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc and Beijing Turing Medical Technology Co. Ltd.; Information on Ethicon Inc (J&J) conducting an interventional clinical trial to evaluate the effectiveness and safety of NeuWave Certus microwave ablation system (MWA) in Chinese patients with primary and secondary tumors in lung are covered in the report..

What’s in it for you?

This report will help tumor ablation devices companies understand the interventional oncology landscape, procedural and technology trends, the brand perception, and competitor activities in China.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the tumor ablation devices market.

The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model.
REPORT COST: 5,000 USD
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.

China Tumor Ablation Landscape Procedure and Technology Trends

Privacy settings